The agreement grants Kyverna Therapeutics access to Oxford Biomedica's LentiVector platform for use with any Kyverna product
LentiVector platform is said to be the first commercially approved lentiviral-based gene delivery system. (Credit: Arek Socha from Pixabay)
Kyverna Therapeutics, a clinical-stage cell therapy company, has entered into a non-exclusive, multi-year licence and supply agreement with Oxford Biomedica, a viral vector contract and development manufacturing organisation (CDMO).
The agreement grants Kyverna Therapeutics access to Oxford Biomedica’s LentiVector platform for use with any Kyverna product.
The LentiVector platform is notable for being the first commercially approved lentiviral-based gene delivery system. It plays a critical role in facilitating the development of groundbreaking gene and cell-based therapies.
Kyverna Therapeutics is working on anti-CD19 chimeric antigen receptor (CAR) T-cell therapies, specifically KYV-101 and KYV-201, which target CD19, a protein found on the surface of B cells.
These therapies have the potential to provide new treatment options for patients who have exhausted current options, particularly those with autoimmune diseases like lupus nephritis.
Currently, Kyverna’s KYV-101 CAR T-cell product is undergoing Phase 1 clinical trials in the US for lupus nephritis, with an additional Phase 1/2 trial taking place in Germany.
Oxford Biomedica chief commercial officer Dr Sebastien Ribault said: “We are committed to quality and innovation. As a world-leading CDMO with expertise across all key viral vector types, we are committed to enabling our biopharma customers to discover and deliver transformative therapies.
“We are excited to work with Kyverna as an innovative leader in cell therapy for autoimmune diseases and look forward to a fruitful partnership.”
Kyverna chief technology officer Karen Walker said: “We are delighted to be working with Oxford Biomedica, a recognised leader in reliable, quality vector supply.
“We value Oxford Biomedica’s extensive capabilities and technologies to enable efficient and cost-effective manufacturing, which is critical in the vast market of B cell-driven autoimmune diseases that our therapies address.”